Helicobacter pylon infection may be associated with duodenal ulcer (DU) and accompanied by enhanced gastrin release but the mechanism ofthis Hpylori related hypergastrinaemia in DU patients is unclear. Cholecystokinin (CCK) has been implicated in the feedback control of gastrin release and gastric acid secretion in healthy subjects. This study therefore investigated if CCK participates in the impairment of postprandial gastrin release and gastric secretion in six DU patients. Tests were undertaken with and without elimination of endogenous CCK by loxiglumide, a selective CCK-A receptors antagonist, before and after eradication of Hpylori with triple therapy (omeprazole, amoxicyllin, bismuth). In H pylon positive DU patients, the postprandial decline in pH (with median pH 3.5) was accompanied by a pronounced increment in plasma gastrin but the administration of loxiglumide did not affect significantly this postprandial rise in plasma gastrin and gastric pH profile. After eradication of H pylon, the plasma gastrin concentration was reduced while the median postprandial pH was significantly increased (median pH 4.3). The administration of loxiglumide resulted in significantly greater increase in postprandial plasma gastrin and greater decrease in pH (median pH 3.1) in these patients. This study shows that (a) infection with H pylori is accompanied by an enhanced gastrin release and gastric acidity in DU patients, (b) the failure of loxiglumide to affect plasma gastrin or gastric acid secretion in Hpylori infected DU patients could be attributed, at least in part, to the failure of endogenous CCK to control gastrin release and gastric secretion by releasing somatostatin, and (c) the test with loxiglumide may be useful in the identification of patients with impaired feedback control of gastrin release and gastric secretion resulting from infection with H pylon. (Gut 1995; 37: 482-487) 
and without elimination of endogenous CCK by loxiglumide, a selective CCK-A receptors antagonist, before and after eradication of Hpylori with triple therapy (omeprazole, amoxicyllin, bismuth). In H pylon positive DU patients, the postprandial decline in pH (with median pH 3.5) was accompanied by a pronounced increment in plasma gastrin but the administration of loxiglumide did not affect significantly this postprandial rise in plasma gastrin and gastric pH profile. After eradication of H pylon, the plasma gastrin concentration was reduced while the median postprandial pH was significantly increased (median pH 4.3) . The administration of loxiglumide resulted in significantly greater increase in postprandial plasma gastrin and greater decrease in pH (median pH 3.1) in these patients. This study shows that (a) infection with H pylori is accompanied by an enhanced gastrin release and gastric acidity in DU patients, (b) the failure of loxiglumide to affect plasma gastrin or gastric acid secretion in Hpylori infected DU patients could be attributed, at least in part, to the failure of endogenous CCK to control gastrin release and gastric secretion by releasing somatostatin, and (c) the test with loxiglumide may be useful in the identification of patients with impaired feedback control of gastrin release and gastric secretion resulting from infection with H pylon. Duodenal ulcer (DU) patients, as a group, tend to secrete more acid than normal subjects both at rest and in response to secretory stimulation.' As, after ingestion of a meal, the important stimulant of gastric acid secretion is an increased plasma gastrin,2-4 the DU patients have been reported to have higher plasma gastrin response to a meal and to exhibit an impaired inhibition of gastrin release at lower intragastric pH. 5 Other studies showed that endogenous cholecystokinin (CCK) may be implicated in the feedback control of gastrin release and gastric acid secretion6 7 because the administration of loxiglumide, a highly selective antagonist of CCK-A receptors,68 greatly enhanced the plasma gastrin and gastric acid secretion in response to ordinary feeding, protein meal or gastrin releasing peptide. Moreover, DU patients were found to exhibit the defect in the inhibitory action of endogenous CCK9-12 on gastric release and gastric acid secretion suggesting an important role of CCK in the feedback control of gastric secretory functions.
The role of CCK as 'enterogastrone' in the control of gastric secretion by duodenal acid or fat has also been tested in dogs using highly selective CCK receptor antagonists such as L-364,718.13 14 These studies confirmed that CCK released by a peptone meal, especially when combined with fat'3 or acid,'4 exerts a potent inhibitory influence on gastric acid secretion and gastrin release through enhancing the release of endogenous somatostatin. Also in DU patients the defect in the inhibitory action of CCK on gastric secretion'0-12 has been suggested to result from the failure of CCK to activate (through the CCK-A receptors) the D cells to release somatostatin because loxiglumide in these patients did not affect significantly the plasma somatostatin concentration. 10 More recently it was found that chronic infection of Hpylori can be found in up to 90% of DU patients and is usually accompanied by non-specific antral gastritis.15-17 It has been suggested that chronic H pylori infection may lead to DU disease because of an inappropriate gastrin release and subsequent enhancement in gastric acid secretion. In other reports reduction in postprandial gastrin responses after eradication of H pylori in DU patients have been shown.1820 Furthermore, studies on asymptomatic (without DU) subjects infected with Hpylori showed that these subjects have a significantly higher peptone meal induced plasma gastrin concentration and significantly attenuated inhibition of plasma gastrin at low intragastric pH compared with uninfected asymptomatic subjects. Throughout the examination period, the intragastric pH was monitored by means of an intraluminal system including the pH antimony electrode (Monocrystal model 9-0215, Synectics AB, Sweden) connected to the portable apparatus, which permitted the pH recording to be sampled every four seconds (Digitrapper MKII, 6200, Synectics AB, Sweden). The antimony electrode used an external reference on the thorax with contact jelly (Hellige 217, Fritz Hellige, Germany). At the beginning and at the end of each examination, the pH electrode was accurately calibrated at 21°C with pH 7.01 and pH 1-07 (buffers 5001 and 5002, Synectics AB, Sweden) and a temperature correction for intragastric reading (37°C) was performed as described before.22 The pH electrode was passed through an anaesthetised nostril and was positioned in the gastric corpus under fluoroscopic control roughly 15 cm below the lower oesophageal sphincter. The pH recording started at about 0800 and lasted four hours and this included 60 minutes of basal period and 180 minutes after digestion of liquid meal.
Data from intragastric pH monitoring were transferred to an IBM compatible computer (80386-IBM) programmed with Gastrogram version 5.50 serial No E1024 (Gastrosoft, Irvine, TX, USA) for calculation of mean and median pH values for each three hour postprandial period. Data from all six subjects treated with placebo and loxiglumide were analysed with the use of program STATpHAC II/PHARM, version 216 D3 (Gastrosoft, Irvine, TX, USA). Gastric acidity was expressed as pH and values from each subject were transferred into 10 minute median values. The median and mean three hour intragastric pHs were pre-defined for comparison between study days using Wilcoxon's signed rank test. Box and whisker plots of median and mean intragastric pH in six patients were calculated for a three hour period after standard meal and compared in medians and means with a significance value of less than 0 05.
Each subject was tested twice before and twice after eradication of H pylori using (a) standard liquid meal with oral administration of a placebo tablet 30 minutes before meal and (b) standard meal and oral administration of a loxiglumide tablet (1200 mg) given 30 minutes before meal.
Eradication of H pylori was achieved with triple therapy including amoxycillin, 500 mg three times daily, for two weeks omeprazole (20 Copenhagen, Denmark) and used in a final dilution of 1:140000. The antibody used recognises G1 7 and G34 equally. The sensitivity of the gastrin measurement in the present assay was 2.5 pmollml serum equivalent to human G-17 as described previously. 23 Plasma CCK concentrations were determined by a radioimmunoassay using antiserum NY 11 (kindly provided by Professor N Yanaihara, Skizuoka, Japan), which recognises the sulphated residue of CCK-8 but has only negligible cross reactivity with sulphated G-1 7 (</5%) and does not cross react with unrelated gastrointestinal peptides. Plasma 
Results
Of 10 H pylon' positive patients initially included in the study, only six had negative histological, rapid urease (CLO test), and 13C urea breath tests four weeks after the end of triple therapy. The results presented in this report concern only the six subjects who showed negative H pylori status and who completed the intragastric pH monitoring tests with placebo and loxiglumide before and after eradication of Hpylori. Figure 1 shows the pH profile recorded during one hour of basal state and during three hours after ingestion of standard liquid meal. The pH value in H pylorn positive patients during the basal period was about 1. 1 and was not significantly different between placebo and loxiglumide treated subjects. With the ingestion of a meal, the median pH immediately rose to about 6 and then slowly declined within about 90 minutes to the pre-meal value, the median pH for three hours of the postprandial period being about 3-5. In subjects treated with loxiglumide, the median pH also rose to pH 6.0 and then declined to the pre-meal value within about 60 minutes, the median pH for the examined period (three hours) being about 3*1. The difference in the median postprandial pH between placebo and loxiglumide treated H pylori positive DU patients was not statistically significant.
The pH profile in DU patients with negative H pylori status, showed similar basal pH value (pH 1-3) and similar pH peak (about pH 6) after ingestion of standard meal. The return of intragastric pH after a meal to the pre-meal value occurred after about 120 minutes in placebo treated subjects and after about 60 minutes in loxiglumide treated subjects. The median pH for the examined period (three hours) was significantly lower in tests with loxiglumide (pH 3-1) than in tests with placebo (pH 4.2).
Basal plasma gastrin, CCK, and somatostatin in placebo treated H pylori positive DU patients averaged 27 (3), 0-8 (0.2), and 3-8 (0.3) pmolI1. Ingestion of a standard liquid meal by those patients treated with placebo resulted in a significant increment (above basal) of plasma concentrations of gastrin (Fig   2) , plasma CCK (Fig 3) , and somatostatin (Fig 4) by about 88%, 150%, and 68%, respectively. In tests with loxiglumide basal plasma hormone concentrations were not significantly affected compared with placebo but the postprandial increments of plasma gastrin and somatostatin were similar to those seen in those patients after treatment with placebo. The increment of meal induced plasma CCK was almost twofold higher in tests with loxiglumide than with placebo.
After eradication of H pylori in DU patients, the basal concentrations of plasma gastrin were significantly reduced, while plasma CCK and * and t for p < acid secretion and that these effects of Hpylori enhanced basal or postprandial plasma gastrin and gastric acid secretion in these patients tostatin values were similar to those in suggesting an impaired inhibition of gastric its before the H pylori eradication. The functions by endogenous CCK possibly caused randial increment in plasma gastrin in by the failure of this CCK to stimulate bo treated patients was similar to that somatostatin release from the D cells.'0-12 The in subjects before the eradication but in implication of somatostatin in the 'enterowith loxiglumide, the increment in the gastrone-like' action of CCK originates from randial plasma gastrin was about twice as the studies on dogs'0 13 14 in which an addition Ls in tests with placebo (Fig 2) . The post-to a peptone meal of fat or acid (which lial increment in plasma CCK concentra-are known releasers of CCK) significantly in H pylori negative DU patients treated inhibited gastrin release and gastric acid secreplacebo were significantly lower than tion. These inhibitory effects were completely in tests with loxiglumide. Thus, the eliminated by the blockade of CCK-A recepnistration of loxiglumide resulted in a tors with L-364,718, a specific antagonist of icant rise in plasma CCK over that seen these receptors. As CCK is known to stimulate acebo treated subjects both before and the release of somatostatin from isolated the eradication of Hpylori (Fig 3) .
canine fundic D cells in vitro29 and the sma somatostatin concentrations showed administration of L-367,718 in vivo also a small increase over basal when a stan-reduced the postprandial release of somatomeal was given to placebo treated patients statin'3 14 it was proposed that the major factor both with H pylorn positive and H pyloni negative status. On the other hand, in H pylori negative DU patients, the increment in plasma somatostatin in tests with loxiglumide was significantly smaller than that in tests with placebo (Fig 4) .
Discussion
This study confirms that eradication of Hpylori in DU patients reduces plasma gastrin release20 24 25 and attenuates the postprandial gastric acid response in these patients. 20 25-28 The most important finding of this study is that the blockade of CCK-A receptors with loxiglumide in DU patients infected with H pylori did not influence significantly the postprandial gastrin concentrations or gastric acid secretion but after eradication of H pylorn in the same patients, loxiglumide resulted in a pronounced increment in plasma gastrin concentrations similar to that seen previously in healthy subjects.6 7 These results could be interpreted that the H pylori infection in DU is responsible for the increased basal plasma gastrin concentrations and increased gastric secretion in response to a meal in these patients. After eradication of H pylon, loxiglumide could suppress the release of somatostatin possibly by antagonising CCK-A receptors localised to these cells. The antagonism of CCK-A receptors and the fall in somatostatin output will remove the G cells from the paracrine inhibitory influence of somatostatin with subsequent excessive postprandial release of gastrin and greatly increased gastric acidity. This is in keeping with our data that after the eradication of H pylori, a significant decrease in basal plasma gastrin and gastric acid responses to the meal was seen but the blockade of CCK-A receptors with loxiglumide resulted in a greatly increased postprandial gastrin release and enhanced gastric acid secretion, similar to those seen in healthy subjects.6 7 As no significant differences in plasma CCK and somatostatin values were seen before and after eradication of H pylori, it is probable that in addition to the proposed CCK-somatostatin-gastrin link there are other factors, such as cytokines (for example, interleukin 1) that may impair the normal physiological feedback loop for gastrin regulation in chronic inflammation resulting from infection by H pylon. Indeed, animals studies32 showed that interleukin 1 given intravenously increased plasma gastrin concentration while inhibiting gastric acid secretion and these effects were mediated by the prostaglandin pathway. Further studies are needed to elucidate the relative contribution of various factors in the control of gastrin release and gastric secretion in the H pylon infected patients.
It is of interest that loxiglumide resulted in a considerable increase in postprandial plasma CCK concentration both in H pylori positive and H pylori negative DU patients. This actually confirms previous findings6 regarding higher postprandial concentrations of circulating CCK in loxiglumide treated patients compared with placebo treated subjects. Higher plasma CCK concentrations in tests with loxiglumide were reported previously in healthy subjects6 11 12 and, according to this study, this is also true for DU patients after eradication of Hpylori.
Our results show that the infection of H pylorn not only enhanced gastrin release but also increased postprandial gastric acid secretion as reported by some investigators'5 24 25 but this is a controversial issue because other reports showed that H pylori infection is accompanied by hypergastrinaemia but not by hyperchlohydria28 33 34 or increased integrated 24 hour intragastric acidity.35
